Study: Antibody Treatment Effective Against Early-Stage Alzheimer's
Above: Eisai Co. signage at the company's headquarters in Tokyo, Japan, on Feb. 3, 2023. Image copyright: Akio Kon/Bloomberg/Getty Images
The Spin
Narrative A
These results show that Alzheimer's patients can maintain cognitive function for years longer than previously thought possible with the proper treatment. The data show that early intervention clearly works, with some patients showing improvement rather than decline, validating investment in amyloid-targeting therapies and supporting broader access to these treatments.
Narrative B
While the data appear promising, the study lacks a proper control group and requires further testing to confirm lecanemab's long-term safety and effectiveness. This is critical for informing healthcare providers about guidelines, costs and patient access — especially given the complexities associated with Alzheimer's diagnosis and treatment.